<p>在昨天发布的一份报告中，美国银行证券的杰森·杰伯里重申了对 Axsome Therapeutics 的买入评级，目标价为 276.00 美元。</p>
<h3>在 TipRanks 上享受 55% 的折扣</h3>
<ul>
<li>解锁对冲基金级别的数据和强大的投资工具，以做出更聪明、更精准的决策</li>
<li>发现表现优异的股票投资理念，并升级到市场领先者的投资组合，使用智能投资者精选</li>
</ul>
<p>杰森·杰伯里给予买入评级是基于与 Auvelity 扩展商业机会和股票估值相关的多种因素。他强调，管理层对 Auvelity 的新目标是 80 亿美元的峰值销售目标，得益于最近在阿尔茨海默病激动症方面的批准和有利标签，这一目标在当前股价中并未完全反映，甚至与更保守的共识峰值估计相比也是如此。</p>
<p>他还指出，即将推出的阿尔茨海默病激动症治疗、扩大到 630 人的销售团队同时推广抑郁症和阿尔茨海默病适应症，以及中枢神经系统药物中指示叠加的证明效益，都是可以释放出显著上行空间的关键增长驱动因素。此外，他提到在重度抑郁症方面的强劲早期进展、上升的重度抑郁症峰值销售假设以及加强的长期管道，这些都支撑了他重申的买入评级和 276 美元的目标价。</p>
<p>根据 TipRanks，杰伯里是一位五星级分析师，平均回报率为 18.9%，成功率为 61.32%。杰伯里覆盖医疗保健行业，关注的股票包括 Ionis Pharmaceuticals、Alkermes 和 BioMarin Pharmaceutical。</p>
<p>在昨天发布的另一份报告中，Needham 也对该股票给予了买入评级，目标价为 267.00 美元。</p>

AXSM

<p>来自美国银行证券的 Jason Gerberry 重申了对 Axsome Therapeutics 的买入评级，并将目标价提高至 276 美元。他指出，Auvelity 在阿尔茨海默病激动症中的商业机会正在扩大，以及管理层 80 亿美元的峰值销售目标是关键因素。即将推出的产品和增强的销售团队预计将推动增长。Needham 也给予了买入评级，目标价为 267 美元。Gerberry 是一位五星级分析师，平均回报率为 18.9%，成功率为 61.32%</p>

<p>In a report released yesterday, Jason Gerberry from Bank of America Securities reiterated a Buy rating on Axsome Therapeutics, with a price target of $276.00.</p>
<div class="lb-trans"><p>在昨天发布的一份报告中，美国银行证券的杰森·杰伯里重申了对 Axsome Therapeutics 的买入评级，目标价为 276.00 美元。</p>
</div><h3>Claim 55% Off TipRanks</h3>
<div class="lb-trans"><h3>在 TipRanks 上享受 55% 的折扣</h3>
</div><ul>
<li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions</li>
<li>Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁对冲基金级别的数据和强大的投资工具，以做出更聪明、更精准的决策</li>
<li>发现表现优异的股票投资理念，并升级到市场领先者的投资组合，使用智能投资者精选</li>
</ul>
</div><p>Jason Gerberry has given his Buy rating due to a combination of factors related to Auvelity’s expanding commercial opportunity and the stock’s valuation. He highlights that management’s new $8 billion peak sales ambition for Auvelity, supported by the recent approval in Alzheimer’s disease agitation and a favorable label, is not fully reflected in the current share price, even versus more conservative consensus peak estimates.</p>
<div class="lb-trans"><p>杰森·杰伯里给予买入评级是基于与 Auvelity 扩展商业机会和股票估值相关的多种因素。他强调，管理层对 Auvelity 的新目标是 80 亿美元的峰值销售目标，得益于最近在阿尔茨海默病激动症方面的批准和有利标签，这一目标在当前股价中并未完全反映，甚至与更保守的共识峰值估计相比也是如此。</p>
</div><p>He also points to the upcoming Alzheimer’s agitation launch, the enlarged 630-person sales force promoting both depression and Alzheimer’s indications, and the proven benefits of indication stacking in CNS drugs as key growth drivers that can unlock substantial upside. Additionally, he notes robust early traction in major depressive disorder, rising peak MDD sales assumptions, and a strengthened longer-term pipeline, all of which underpin his reiterated Buy rating and increased price objective of $276 per share.</p>
<div class="lb-trans"><p>他还指出，即将推出的阿尔茨海默病激动症治疗、扩大到 630 人的销售团队同时推广抑郁症和阿尔茨海默病适应症，以及中枢神经系统药物中指示叠加的证明效益，都是可以释放出显著上行空间的关键增长驱动因素。此外，他提到在重度抑郁症方面的强劲早期进展、上升的重度抑郁症峰值销售假设以及加强的长期管道，这些都支撑了他重申的买入评级和 276 美元的目标价。</p>
</div><p>According to TipRanks, Gerberry is a 5-star analyst with an average return of 18.9% and a 61.32% success rate. Gerberry covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Alkermes, and BioMarin Pharmaceutical.</p>
<div class="lb-trans"><p>根据 TipRanks，杰伯里是一位五星级分析师，平均回报率为 18.9%，成功率为 61.32%。杰伯里覆盖医疗保健行业，关注的股票包括 Ionis Pharmaceuticals、Alkermes 和 BioMarin Pharmaceutical。</p>
</div><p>In another report released yesterday, Needham also assigned a Buy rating to the stock with a $267.00 price target.</p>
<div class="lb-trans"><p>在昨天发布的另一份报告中，Needham 也对该股票给予了买入评级，目标价为 267.00 美元。</p>
</div>

Buy Rating Reiterated as Auvelity’s Expanded Alzheimer’s Opportunity Drives Upgraded $276 Price Target

- 美国银行证券的杰森·杰伯里重申对 Axsome Therapeutics 的买入评级，目标价 276 美元。  
- 杰伯里认为管理层的 80 亿美元销售目标未在当前股价中完全反映。  
- 近期阿尔茨海默病激动症的批准预计将推动公司增长。

Tip Ranks

Axsome Therap

美国银行

Ionis制药

阿尔凯默斯

拜玛林制药

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

由于 Auvelity 在阿尔茨海默症领域的扩展机会，买入评级被重申，目标价上调至 276 美元